The News

We are excited to announce that Diag-Nose has officially moved into a cutting-edge laboratory facility at CoLabs Notting Hill, marking a significant milestone in our growth and research capabilities. This new space is designed to support advanced biomarker discovery, assay development, and clinical validation, reinforcing our commitment to driving innovation in precision respiratory medicine.

CoLabs provides a state-of-the-art infrastructure, fostering collaboration with leading biotech and medtech startups. Our new facility is equipped to accelerate our RhinoMAP biomarker platform, optimize the ABEL nasal microsampler, and streamline the transition from research to real-world clinical applications.

Why This Matters

Expanding into a dedicated lab facility unlocks key opportunities for Diag-Nose, including:

✅ Enhanced R&D capacity to refine and scale our diagnostic technologies.
✅ Access to specialized equipment for high-throughput biomarker analysis.
✅ A collaborative environment to engage with industry experts, partners, and researchers.
✅ Closer proximity to existing collaborators at Monash Health and Monash University.

This move strengthens our ability to develop next-generation diagnostic solutions and positions us at the forefront of biomarker-driven precision medicine.

What’s Next?

With our new lab operational, we will scale up biomarker research, optimize assay development, and advance our clinical validation pipeline. Our team will also be expanding collaborations with industry partners, researchers, and clinicians to accelerate the adoption of nasal fluid diagnostics in respiratory care.

👉 Follow us on LinkedIn for a behind-the-scenes look at our new lab and stay updated on our latest breakthroughs in precision diagnostics! 🚀